News

Singapore Telecommunications Reports Strong Profit Growth

1 Mins read

Singapore Telecommunications (Singtel) has announced a significant rise in net profit for the first six months of the year, driven primarily by a one-off gain from its Indonesia associate, Telkomsel. The telecom operator reported a net profit of SGD 2.14 billion (USD 1.58 billion), representing an 83% increase compared to the same period last year.

Singtel attributed its strong performance to a SGD 1.21 billion one-off gain resulting from a reduction in its effective equity interest in Telkomsel. The company also revealed plans to increase its dividend payout ratio by 10 percentage points, aiming for a range of 70%-90% of its underlying net profit.

However, Singtel reported a 3.0% decline in revenue to SGD 7.03 billion, impacted by the depreciation of the Australian dollar and lower contributions from its Singapore business. Amid weak sentiment and reduced spending on information and communications technology, Singtel’s Singapore operations faced challenges.

Singtel expects capital expenditure for the fiscal year to total around SGD 2.1 billion, with a significant portion allocated to its Australian business. The company also anticipates continued currency headwinds due to the strength of the Singapore dollar relative to the Australian and regional currencies.

Related posts
News

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…
News

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…
News

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 69 = 71